Capricor Therapeutics (CAPR) EBIAT (2016 - 2025)
Historic EBIAT for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$24.6 million.
- Capricor Therapeutics' EBIAT fell 9567.71% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.2 million, marking a year-over-year decrease of 10565.6%. This contributed to the annual value of -$40.5 million for FY2024, which is 8156.86% down from last year.
- Capricor Therapeutics' EBIAT amounted to -$24.6 million in Q3 2025, which was down 9567.71% from -$25.9 million recorded in Q2 2025.
- Capricor Therapeutics' 5-year EBIAT high stood at -$762089.0 for Q4 2023, and its period low was -$25.9 million during Q2 2025.
- Over the past 5 years, Capricor Therapeutics' median EBIAT value was -$7.2 million (recorded in 2023), while the average stood at -$9.2 million.
- In the last 5 years, Capricor Therapeutics' EBIAT soared by 9012.95% in 2023 and then tumbled by 83382.83% in 2024.
- Over the past 5 years, Capricor Therapeutics' EBIAT (Quarter) stood at -$6.2 million in 2021, then dropped by 24.72% to -$7.7 million in 2022, then skyrocketed by 90.13% to -$762089.0 in 2023, then plummeted by 833.83% to -$7.1 million in 2024, then tumbled by 245.26% to -$24.6 million in 2025.
- Its EBIAT stands at -$24.6 million for Q3 2025, versus -$25.9 million for Q2 2025 and -$7.1 million for Q4 2024.